SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Stanolone / Dihydrotestosterone | Testosterone | Finasteride |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Endogenous androgen and non-aromatisable androgen medicine in limited jurisdictions | Endogenous androgen / prescription androgen medicine | Type II 5-alpha-reductase inhibitor medicine |
| PrimeCore Class | Class BInvestigational | Class AApproved in a bounded context | Class AApproved in a bounded context |
| Evidence Grade | Grade DLimited / observational evidence | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Stanolone / Dihydrotestosterone is classified here as Endogenous androgen and non-aromatisable androgen medicine in limited jurisdictions. Endogenous biology and country-specific products do not authenticate supplier injections or establish performance benefit. No current FDA-approved injectable stanolone product was identified; prohibited by WADA at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Testosterone is an endogenous androgen and an active ingredient in authorised prescription medicines, but 'Test' does not identify an ester, formulation, strength, manufacturer or authorisation. Cypionate, enanthate, undecanoate, propionate, no-ester formulations and blends are not automatically interchangeable. TRAVERSE found MACE noninferiority for a specific gel in a defined population while other safety signals remained. This evidence does not authenticate catalogue products or support performance use. WADA 2026 prohibits testosterone and its esters at all times. | Finasteride is classified here as Type II 5-alpha-reductase inhibitor medicine. Randomised and label evidence supports defined benign-prostatic-hyperplasia and androgenetic-alopecia products. FDA-authorised prescription products exist for defined indications; the catalogue name does not establish product approval. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions